LifeStance Health Group, Inc.
NASDAQ:LFSTMedical - Care Facilities
+$0.17 today
- Market cap
- $5.24B
- Beta
- 1.19
- P/E (TTM)
- 146.6
- EPS (TTM)
- $0.06
Volume 6.60M
Average 3.91M
LFST Net Income
Bottom-line profit, the starting point for calculating cash from operations.
LifeStance Health Group, Inc.NASDAQ: LFST
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $23.61M, compared with -$3.79M a year earlier. Trailing-twelve-month net income was $50.6M.
Context
- Net income amounted to 0.7% of revenue in FY2025, down 3.9 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of $79.89M (+726.8%) for the fiscal year ending Dec 2026, a step up from the +116.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $23.61M+65.8% QoQ
- Last fiscal yearDec 2025
- $9.66M+116.8% YoY
- LTMJun 2026
- $50.6M+413.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +722.8% | +1239.3% | +516.5 pp |
| 1 year | +116.8% | +726.8% | +609.9 pp |
| 3-year CAGR | — | +163.5% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 9.66M USD
- Year-over-year change
- +116.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.66M | +116.8% |
| FY2024 | 2024-12-31 | (57.44M) | +69.2% |
| FY2023 | 2023-12-31 | (186.26M) | +13.6% |
| FY2022 | 2022-12-31 | (215.56M) | +29.8% |
| FY2021 | 2021-12-31 | (307.2M) | — |
Net Income vs competitors
How LFST compares with its peers on the latest reported figures
- LFST's LTM Jun 2026 net income of $50.6M is the 5th largest of the 7 companies compared; the peer median is $14.32M.
- Its year-over-year change of +413.3% is the highest of 7, against a peer median of +45.4%.
- Net income amounts to 3.2% of revenue for LFST, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.53B | +19.5% | +32.0% | 8.4% | |
| LTM Sep 2026 | $1.12B | -1051.3% | — | 32.9% | |
| LTM Sep 2026 | $336.27M | +164.4% | — | 2.2% | |
| LTM Sep 2026 | $190.84M | -242.6% | — | 6.7% | |
| LTM Jun 2026 | $50.6M | +413.3% | — | 3.2% | |
| LTM Jun 2026 | $28.12M | +71.4% | — | 1.2% | |
| LTM Mar 2026 | $507.37K | +105.0% | — | 0.2% | |
| Peer median (excluding LFST) | $14.32M | +45.4% | +32.0% | 4.4% | |
Competitors are the stored peer set for LFST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (307.2M) | (215.56M) | (186.26M) | (57.44M) | 9.66M |
| Depreciation & Amortization | 54.14M | 69.2M | 80.44M | 70.95M | 54.75M |
| Deferred Income Tax | (26.95M) | (16.73M) | (21.92M) | (958K) | 2.42M |
| Stock-Based Compensation | 259.44M | 187.43M | 99.39M | 76.17M | 74.7M |
| Change in Working Capital | 2.14M | (16.94M) | (33.72M) | (27.37M) | (40.34M) |
| Accounts Receivables | (24.21M) | (21.66M) | (24.18M) | (6.4M) | 36.09M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 623K | 7.67M | (5.61M) | 501K | (1.56M) |
| Other Working Capital | 25.73M | (2.94M) | (3.94M) | (21.47M) | (74.87M) |
| Other Non-Cash Items | 27.85M | 45.4M | 45.2M | 45.91M | 44.96M |
| Operating Cash Flow | 9.42M | 52.79M | (16.88M) | 107.26M | 146.15M |
| Capital Expenditures | (94.49M) | (79.26M) | (40.52M) | (21.57M) | (36.13M) |
| Acquisitions (Net) | (99.58M) | (60.21M) | (19.82M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (194.08M) | (139.46M) | (60.34M) | (21.57M) | (36.13M) |
| Debt Repayment | (223.77M) | 69.56M | 55.28M | (1.69M) | (7.25M) |
| Common Stock Issued | 549.91M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (904K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.28M) | (21.39M) | (7.86M) | (8.26M) | (8.71M) |
| Financing Cash Flow | 313.86M | 47.26M | 47.43M | (9.95M) | (15.96M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 129.2M | (39.41M) | (29.8M) | 75.75M | 94.07M |
| Free Cash Flow | (85.07M) | (26.47M) | (57.4M) | 85.69M | 110.03M |
LifeStance Health Group, Inc.
NASDAQ:LFST
Intrinsic Alpha fair value
Locked
Current Price
$13.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.